In 2025, sales increased by 9.9% at constant exchange rates, while business EPS improved significantly faster by 15.0%. The company leverages AI-driven supply chain management that enabled it to avoid $300 million in revenue risk, and combining machine learning with lab research has helped discover 10 completely new drug targets in just one year.
Cyborg Score Rationale
Sanofi reported 9.9% sales growth for 2025, reaching EUR 43.6 billion, and delivered 13.3% sales growth in Q4. The company expects sales to grow by a high single-digit percentage in 2026 with business EPS growing slightly faster than sales. Strong pipeline execution and AI integration position the company well, though patent cliffs and pricing pressures present ongoing challenges.
Top Insights
Dupixent achieved EUR 15.7 billion in sales with over 30% patient growth, while three new medicines and vaccines (Qfitlia, Wayrilz, Nuvaxovid) were launched in 2025 and ALTUVIIIO and Beyfortus achieved blockbuster status.
The company delivered 12 Phase III and 15 Phase II readouts, 20 regulatory approvals, and multiple late-stage programs advancing in 2025.
AI agents are actively shaping decision-making in drug development, assessing whether drugs should advance to the next trial phase and comparing asset prospects against others in development.
Sanofi reached agreement with the US government to lower medicine costs while strengthening innovation.
Named Competitors
Dupixent — Leading biologic for atopic dermatitis and other inflammatory conditions
Keytruda — Leading oncology immunotherapy
Rinvoq — JAK inhibitor for inflammatory conditions
Otezla — Small molecule immunology therapy
Recent Developments
(January 2026) Strategic investment of up to $25 million in Adagene for masked antibody therapy collaboration
(December 2025) Acquired Dynavax to add hepatitis B vaccine and shingles candidate to portfolio
(December 2025) Wayrilz approved in EU as first BTK inhibitor for immune thrombocytopenia
(January 2026) Tzield accepted for priority review in US for young children with type 1 diabetes
Open the full interactive Sanofi S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.